Douglas Flora: How AI Is Revolutionizing Oncology in Diagnosis, Treatment, and Research
Douglas Flora shared on LinkedIn:
“Thanks to Targeted Oncology for having me on to discuss. I’m on a mission to get providers and administrators to prioritize these tools in a more imtentional way. Once you start to read this literature and experiment yourself, you won’t need convincing.
Take it from someone reading the studies every day—if this isn’t rising to the top of your strategic planning today, you are missing the opportunity of your lifetime to help your patients and your systems survive.
A quote from our interview:
‘AI is the next generation of oncology health, which is saying we have to be the best at getting better for our patients. We cannot be comfortable where we are today,’ Flora shares. ‘Things are getting better rapidly, and these tools are here to augment your ability to do the right thing for your patient every time.'”
More posts featuring Douglas Flora.
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023